Tonix Pharmaceuticals Holding Corp.

Listed Company

TNXPCIK 0001430306NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

$13.11M

Net Income

—

Total Assets

$277.17M

Equity

$245.15M

Shares Out

15.94M

Op. Cash Flow

$-99.84M

TNXP$12.37−73.76% · past yearDBEQ Basic

Daily closing prices

Business

Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company markets TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia and two FDA-approved migraine products, Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). Its development pipeline includes multiple candidates in clinical and preclinical stages across CNS indications, organ transplant rejection, Lyme disease prevention, rare diseases, and infectious disease vaccines.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product revenue, net	13	10	8	—	—
Cost of sales	7	8	5	—	—
Research and development	44	40	87	82	69
Selling, general and administrative	88	40	35	30	—
Asset impairment charges	—	59	—	—	—
Total Operating Expenses	139	147	126	112	92
Operating loss	−126	−137	−118	−112	−92
Grant income	3	3	—	—	—
Gain on change in fair value of warrant liabilities	—	6	—	—	—
Loss on extinguishment of debt	−2	0	—	—	—
Interest income	4	22,000	2	2	25,000
Interest expense	−89,000	−1	—	—	—
Other expense, net	−3	−867,000	2	—	—
Net loss available to common stockholders	−124	−130	−117	−117	−92
Net loss to common stockholders per common share, basic	−14.57	−176.6	−14,720	−20.01	−8.1
Net loss to common stockholders per common share, diluted	−14.57	−176.6	−14,720	−20.01	−8.1
Weighted average common shares outstanding, basic	9	736,339	7,925	6	11
Weighted average common shares outstanding, diluted	9	736,339	7,925	6	11

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	208	99	25	120	179
Accounts receivable, net	6	4	—	—	—
Inventory	6	8	—	—	—
Prepaid expenses and other current assets	9	8	9	11	10
Total current assets	229	119	48	131	189
Property and equipment, net	44	42	94	94	51
Intangible assets, net	120,000	120,000	10	120,000	120,000
Operating lease right-to-use assets	2	565,000	824,000	715,000	914,000
Other non-current assets	2	951,000	1	264,000	379,000
Total assets	277	163	154	226	241
Accounts payable	8	5	4	8	13
Accrued expenses and other current liabilities	23	11	12	10	8
Term loan payable, short term	—	3	2	—	—
Lease liability, short term	125,000	274,000	270,000	432,000	489,000
Total current liabilities	31	18	19	18	22
Term loan payable, long term	—	5	7	—	—
Lease liability, long term	1	358,000	632,000	328,000	467,000
Total liabilities	32	23	49	19	22
Commitments (See Note 17)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares designated as of both December 31, 2025 and 2024; 0 shares issued and outstanding - as of both December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 12,788,069 and 4,385,929 shares issued and outstanding as of December 31, 2025 and 2024, respectively and 5,883 shares to be issued as of December 31, 2025	13,000	4,000	—	12,000	16,000
Additional paid in capital	1,100	871	706	677	579
Accumulated deficit	−855	−731	−601	−470	−360
Accumulated other comprehensive loss	−289,000	−255,000	−232,000	−167,000	−92,000
Total stockholders equity	245	140	106	207	219
Total liabilities and stockholders equity	277	163	154	226	241

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	2	3	4	1	50,000
Bad debt expense	31,000	—	—	—	—
Stock-based compensation	6	5	9	11	8
Change in fair value of warrant liabilities	—	−6	283,000	—	—
Loss on note	1	0	—	—	—
Inventory write-off	669,000	1	—	—	—
Amortization of debt discounts	65,000	840,000	—	—	—
Issuance costs of derivative instrument	2	—	—	—	—
Accounts receivable	−3	−4	—	—	—
Inventory	2	4	61,000	—	—
Prepaid expenses and other	−3	4	2	−164,000	518,000
Accounts payable	3	927,000	−3	−1	4
Operating lease liabilities and ROU asset, net	−303,000	−13,000	35,000	2,000	−11,000
Accrued expenses and other current liabilities	12	1	2	1	2
Net cash used in operating activities	−100	−61	−102	−98	−76
Issuance of note	−2	—	—	—	—
Proceeds from note	853,000	—	—	—	—
Purchase of property and equipment	−3	−120,000	−8	−48	−35
Net cash used in investing activities	−5	−120,000	−29	−48	−35
Deferred payment related to purchase of business	—	−3	—	—	—
Proceeds from ESPP	—	27,000	29,000	40,000	96,000
Repayments of term loan	−10	−2	—	—	—
Proceeds, net of $8,750 and $7,238 expenses, from sale of common stock and warrants, respectively	238	140	19	94	212
Repurchase of common stock, net of $30 expenses	−14	—	−14	—	—
Net cash provided by financing activities	215	135	37	88	212
Effect of currency rate change on cash	−31,000	4,000	−65,000	−74,000	−31,000
Net increase in cash, cash equivalents and restricted cash	110	74	−95	−58	102
Interest paid	89,000	1	88,000	—	—
Purchases of property and equipment included in accounts payable and accrued liabilities	865,000	—	106,000	3	7
Net ATM proceeds received after year-end	—	2	—	—	—
Issuance costs from derivative instruments	2	—	—	—	—
New operating leases and lease amendments	1	—	898,000	386,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Tonix Pharmaceuticals Holding Corp.'s CIK number?

Tonix Pharmaceuticals Holding Corp.'s SEC CIK number is 0001430306 (1430306). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Tonix Pharmaceuticals Holding Corp.'s SEC filings?

All of Tonix Pharmaceuticals Holding Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Tonix Pharmaceuticals Holding Corp. last report earnings?

Tonix Pharmaceuticals Holding Corp. (TNXP) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001999371-26-010487). This is Tonix Pharmaceuticals Holding Corp.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Tonix Pharmaceuticals Holding Corp.'s most recent earnings 8-K?

Tonix Pharmaceuticals Holding Corp.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001999371-26-010487. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Tonix Pharmaceuticals Holding Corp.'s latest earnings 8-K →
Look up any company's CIK number →